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Abstract
Background: The World Health Organization (WHO), like many other organisations around the world, has recognised
the need to use more rigorous processes to ensure that health care recommendations are informed by the best available
research evidence. This is the last of a series of 16 reviews that have been prepared as background for advice from the
WHO Advisory Committee on Health Research to WHO on how to achieve this.
Objectives: We reviewed the literature on evaluating guidelines and recommendations, including their quality, whether
they are likely to be up-to-date, and their implementation. We also considered the role of guideline developers in
undertaking evaluations that are needed to inform recommendations.
Methods: We searched PubMed and three databases of methodological studies for existing systematic reviews and
relevant methodological research. We did not conduct systematic reviews ourselves. Our conclusions are based on the
available evidence, consideration of what WHO and other organisations are doing and logical arguments.
Key questions and answers: Our answers to these questions were informed by a review of instruments for evaluating
guidelines, several studies of the need for updating guidelines, discussions of the pros and cons of different research
designs for evaluating the implementation of guidelines, and consideration of the use of uncertainties identified in
systematic reviews to set research priorities.
How should the quality of guidelines or recommendations be appraised?
• WHO should put into place processes to ensure that both internal and external review of guidelines is undertaken
routinely.
• A checklist, such as the AGREE instrument, should be used.
• The checklist should be adapted and tested to ensure that it is suitable to the broad range of recommendations that
WHO produces, including public health and health policy recommendations, and that it includes questions about equity
and other items that are particularly important for WHO guidelines.
When should guidelines or recommendations be updated?
• Processes should be put into place to ensure that guidelines are monitored routinely to determine if they are in need
of updating.
• People who are familiar with the topic, such as Cochrane review groups, should do focused, routine searches for new
research that would require revision of the guideline.
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• Consideration should be given to establishing guideline panels that are ongoing, to facilitate routine updating, with
members serving fixed periods with a rotating membership.
How should the impact of guidelines or recommendations be evaluated?
• WHO headquarters and regional offices should support member states and those responsible for policy decisions and
implementation to evaluate the impact of their decisions and actions by providing advice regarding impact assessment,
practical support and coordination of efforts.
• Before-after evaluations should be used cautiously and when there are important uncertainties regarding the effects of
a policy or its implementation, randomised evaluations should be used when possible.
What responsibility should WHO take for ensuring that important uncertainties are addressed by future
research when the evidence needed to inform recommendations is lacking?
• Guideline panels should routinely identify important uncertainties and research priorities. This source of potential 
priorities for research should be used systematically to inform priority-setting processes for global research.
Background
The World Health Organization (WHO), like many other
organisations around the world, has recognised the need
to use more rigorous processes to ensure that health care
recommendations are informed by the best available
research evidence. This is the last of a series of 16 reviews
that have been prepared as background for advice from
the WHO Advisory Committee on Health Research to
WHO on how to achieve this.
Providing technical advice to its member states is a core
function of the World Health Organization (WHO).
Ensuring the quality of the advice that is given is an inher-
ent responsibility of WHO. In this paper we address the
following questions related to evaluation of guidelines
and their implementation:
• How should the quality of guidelines or recommenda-
tions be appraised?
• When should guidelines or recommendations be
updated?
• How should the impact of guidelines or recommenda-
tions be evaluated?
• What responsibility should WHO take for ensuring that
important uncertainties are addressed by future research
when the evidence needed to inform recommendations is
lacking?
Related questions regarding updating of systematic
reviews and implementation are addressed in other arti-
cles in this series [1,2].
What WHO is doing now
The Guidelines for WHO Guidelines suggest that draft
guidelines should be subjected to a self-test by the techni-
cal development and the steering/liaison groups using a
checklist (Table 1) [3].
However, the checklist is not being used and most guide-
lines appear to be deficient [4]. An unpublished, in house
review of WHO guidelines using the AGREE appraisal
instrument [5] found that the vast majority of guidelines
did not meet most of the AGREE criteria [6]. Although
draft guidelines are often sent for peer review, and the
Guidelines for WHO Guidelines suggests external review,
this is not always done. WHO's Regulations for Expert
Committees, in fact, require that "The expert committee
shall draw up and approve its report before the closure of its
meeting." [7]
We are not aware of any assessments of the extent to
which WHO guidelines, recommendations or policies are
kept up to date or any policies for withdrawing ones that
are out of date. The Guidelines for WHO Guidelines offers
the following encouragement for undertaking rigorous
studies to provide missing evidence, but we are not aware
of any other policies linking important uncertainties in
guidelines to WHO's priorities for research: "Sometimes it
will be necessary to issue guidelines where no rigorous studies
exist, based on the best available evidence. But after issuance of
such guidelines, the opportunity could be taken to undertake
rigorous studies to provide missing evidence and to evaluate the
effectiveness or impact of the guidelines in the actual settings
where they are intended to be used. This would allow them to
be revised or updated if needed."
What other organisations are doing
In a survey of 152 organizations that produce guidelines,
technology assessments, or support the use of research inPage 2 of 7
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both an internal review process (80%) and external review
by experts (82%) [8]. Only 44% reported external review
by target users (58% of guideline producers), 43%
reported comparing their products with products or input
from other groups, and 31% reported using pilot testing.
Fifty-two percent of the units that produced guidelines
reporting updating them regularly and 45% reported
updating irregularly. Thirty-five percent reported collect-
ing data about uptake systematically, and 32% reported
systematically evaluating the usefulness or impact of their
guidelines in some other way.
Table 1: Checklist for WHO Treatment Guidelines (from Guidelines for WHO Guidelines [3]).
Yes Questions Reference Points
Origin
1 Are the Cluster and Department issuing the guidelines clearly identified? Introduction
Objective, target audience
2 Does the guideline list its objectives, including the patient categories and situation(s) 
for which the guidelines are intended?
Introduction
3 Does the guideline describe the professional groups to which it is addressed? Introduction
Guideline Development Group
4 Does the Guideline Development Group include all relevant professional groups, 
public health experts and end users, including individuals from geographic areas 
where the guidelines will be applied?
List of members of the guideline development 
group
5 Does the Group include methodological experts in fields such as search 
methodology, critical appraisal and cost-effectiveness analysis?
List of members of the guideline development 
group
Conflict of interest
6 Are all funding sources named, and is there no conflict of interest? List of funding sources
7 Have all members of the Guideline Development Group and external reviewers 
declared their interests, and have these interests been recorded in the guideline 
document?
Annex on documentation of process
8 Does the document describe the method used to minimize any undue influence on 
the Guideline Development Group and the external reviewers?
Annex on documentation of process
Evidence
9 Was there a systematic comprehensive search for evidence, and has the search 
strategy been recorded in the guideline?
Annex on documentation of process
10 Has the strength and quality of the evidence on effectiveness been graded? Annex on documentation of process; evidence 
table
11a What percent of recommendations are evidence-based?* Summary of recommendations
11b Are the recommendations which are not evidence-based explicitly labeled as "expert 
opinion" based?
Summary of recommendations
12 Is there explicit consideration of other issues, such as safety and potential misuse in a 
variety of settings?
Annex on documentation of process; evidence 
table
13 Is there explicit consideration of issues of cost effectiveness? Annex on documentation of process; evidence 
table
14 Is the strength of the recommendation linked to the evidence? Summary of Recommendations
15 Do the recommendations take into account potential resource constraints? Implementation issues
Review
16 Were the comments by the external peer review adequately addressed? Annex on documentation of process
17 Did all members of the Guideline Development Group approve the final document? Annex on documentation of process
18 Did all members of the Steering Group approve the final document? Annex on documentation of process
19 Is there a plan for reviewing new evidence and updating the guideline? Introduction
Presentation, clarity
20 Are the recommendations clearly formulated? Summary of Recommendations
21 Does the guideline identify and advise on ineffective practices? Summary of Recommendations
Implementation plan
22 Is there a plan for dissemination and local adaptation of the guideline? Companion document
23 Are funds available for dissemination and local adaptation for the guideline? Companion document
24 Are there suggested criteria for monitoring the use in intended settings? Implementation Issues
This Checklist is intended for the following purposes: (1) As a guide for developing or updating WHO treatment Guidelines. (2) As a check-list for 
Executive and Regional Directors when giving final approval for publication. To qualify for publication and inclusion in the WHO database of 
treatment guidelines, a tick mark signifying YES must be placed beside all the 24 criteria, except 11a.
*These are recommendations based on information other than expert opinion.Page 3 of 7
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ment programs, more than half reported monitoring or
evaluating the effects of at least some guidelines. All
reported using some type of quality system for good
guideline development. Eleven used both external and
internal review, six used external review only, and one
internal review only. In addition seven compared their
guidelines with guidelines from other groups and three
used pilot testing. All reported updating their guidelines at
least occasionally, although only half had formal update
procedures.
Methods
The methods used to prepare this review are described in
the introduction to this series [9]. Briefly, the key ques-
tions addressed in this paper were vetted amongst the
authors and the ACHR Subcommittee on the Use of
Research Evidence (SURE). We did not conduct a full sys-
tematic review. We searched PubMed and three databases
of methodological studies (the Cochrane Methodology
Register, the US National Guideline Clearinghouse, and
the Guidelines International Network for existing system-
atic reviews and relevant methodological research that
address these questions. The answers to the questions are
our conclusions based on the available evidence, consid-
eration of what WHO and other organisations are doing,
and logical arguments.
For this review we used articles that we had previously
identified, including a review of clinical practice guideline
appraisal instruments [10], to locate related articles in
PubMed; we searched the National Guidelines Clearing-
house annotated bibliography using the category guide-
line evaluation with the terms appraisal or impact, and for
all categories using updating; and we checked the refer-
ence lists of retrieved articles. We also searched for and
scanned reviews of methods for setting research priorities
that were linked to guidelines development programs by
searching PubMed for reviews of research priorities, for
articles that addressed both research priorities and prac-
tice guidelines, and by searching the Web using Google for
sites that addressed methods for setting priorities for
research and global research priorities.
Findings
How should the quality of guidelines or recommendations 
be appraised?
Graham and colleagues in a systematic review of instru-
ments for assessing the quality of clinical practice guide-
lines found 13 instruments published up to 1999 [10]. All
instruments were developed after 1992 and contained 8
to 142 questions or statements. Only the Cluzeau instru-
ment, which formed the basis of the AGREE instrument
[11,12]' included at least one item for each of the 10
attributes that the authors identified across instruments.
This instrument and that of Shaneyfelt and colleagues
[13]. were the only instruments that had been validated.
They concluded that there was insufficient evidence to
support the exclusive use of any one instrument, although
the AGREE instrument has received the most evaluation.
Vlayen and colleagues updated the review by Graham and
colleagues up to 2003 [14]. They found 24 different
appraisal tools. The 24 instruments included a total of
469 questions that they also grouped into 10 dimensions:
validity, reliability/reproducibility, clinical applicability,
clinical flexibility, multidisciplinary process, clarity,
scheduled review, dissemination, implementation, and
evaluation. They found three instruments that addressed
all 10 dimensions and three additional instruments based
on the Cluzeau instrument, one of which, the AGREE
instrument, was the only one to have been validated. They
found that the AGREE instrument was a validated, easy-
to-use, and transparent instrument, which was interna-
tionally developed and widely accepted, but noted two
limitations that they considered important: although it
can be used to compare clinical practice guidelines, it does
not set a threshold to classify them as good or bad, and it
does not assess the quality of the evidence supporting the
recommendations.
The AGREE instrument was developed through a process
of item generation, selection and scaling, field-testing and
refinement [5]. The final version of the instrument con-
tained 23 items grouped into six domains: scope and pur-
pose, stakeholder involvement, rigour of development,
clarity and presentation, applicability, and editorial inde-
pendence.
When should guidelines or recommendations be updated?
Shekelle and colleagues, based on a review of 17 guide-
lines published by AHRQ, estimated that no more than
90% were still valid after 3.6 years and that about half the
guidelines were outdated in 5.8 years. They recommend
that guidelines should be reassessed every three years,
based on the lower 95% confidence interval for their esti-
mate of when one of ten guidelines would no longer be
up-to-date. They suggest several ways of expeditiously
assessing the need for updating guidelines including con-
ducting limited searches by groups that are familiar with
the topic, such as Cochrane review groups, focusing
searches on research that the guidelines panel considered
would play a pivotal role in requiring revision of the
guideline, periodic review of the guidelines by experts not
involved in developing the guidelines, and considering
guidelines development as an ongoing process, rather
than a discreet event, with members of guideline panels
serving fixed periods with a rotating membership.
Gartlehner and colleagues compared the approach sug-
gest by Shekelle and colleagues of a limited search usingPage 4 of 7
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tional process using typical systematic review methods in
terms of comprehensiveness and effort [15]. They applied
both approaches independently to assess the need to
update six topics from the 1996 Guide to Clinical Preven-
tive Services from the US Preventive Services Task Force
[16]. They found that although the limited search
approach identified fewer eligible studies than the tradi-
tional approach, none of the studies missed was rated as
important by task force members acting as liaisons to the
project with respect to whether the topic required an
update. On average, this approach produced substantially
fewer citations to review than the traditional approach.
The effort involved and potential time saving depended
largely on the scope of the topic. They found that involv-
ing experts in assessing how current the guidelines were
was not helpful, in contrast to Shekelle and colleagues.
Johnston and colleagues found that an updating strategy
for cancer practice guidelines identified 80 pieces of new
evidence over a one-year period relating to 17 of 20 guide-
lines [17]. They found on average four pieces of new evi-
dence per guideline, but there was considerable variation
across the guidelines. Of the 80 pieces, 19 contributed to
modifications of clinical recommendations in six practice
guidelines, whereas the remaining evidence supported the
original recommendations. Their updating process
yielded important findings, but was resource intensive.
They found that it would be possible to reduce the scope
of the sources searched routinely to MEDLINE, the
Cochrane Library and meeting proceedings.
The findings of these three studies of the need to update
guidelines is consistent with findings from studies of the
need to update systematic reviews, which generally sup-
port the conclusion that in situations where time or
resources are limited, thorough quality assessments
should likely take precedence over extensive literature
searches [1].
How should the impact of guidelines or recommendations 
be evaluated?
Strategies ranging from passive dissemination to inten-
sive, complex interventions have been used to implement
guidelines and a range of study designs has been used to
evaluate the impact of these strategies using a range of
outcome measures [18,19]. Passive strategies have often
not been effective, however there is limited evidence to
support decisions about which guideline dissemination
and implementation strategies are likely to be efficient
under different circumstances [2,18].
Study designs that can be used to evaluate the impact of
guidelines include randomised designs, particularly clus-
ter randomised trials, a range of observational study
designs, including interrupted time series analyses, con-
trolled before-after studies and uncontrolled before-after
studies [20]. The advantage of using randomised designs
for impact assessments is that they give greater confidence
that the measured impact of a program is attributable to
whatever implementation strategy was used and not to
some other factor [21-23]. It is generally not possible to
predict differences in the size, or even the direction, of
estimates of treatment effects for the same intervention
when it is generated in randomized and non-randomized
studies [22]. There have been similar findings for impact
evaluations of development programs [21] and imple-
mentation strategies. For example, a systematic review of
continuous quality improvement found improvements in
41 of 43 single site before-after studies and most of 13
multi site before-after studies, but no improvements in
three randomised trials [24].
A wide variety of techniques to gather data have been used
singly or in combinations, including questionnaires,
interviews, observation, audit and using routinely col-
lected data. Self-report may not be consistent with more
objective measures of practice. Collecting reliable data in
low and middle-income countries (LMIC) can be a major
challenge, where available records and routinely collected
data may be lacking. We did not find any systematic
reviews of strategies for collecting data for impact evalua-
tions in LMIC.
What responsibility should WHO take for ensuring that 
important uncertainties are addressed by future research 
when the evidence needed to inform recommendations is 
lacking?
Priority-setting exercises for global health research have
used various methods and processes [25]. We have not
found examples of priority setting programs based on
important uncertainties identified in guidelines. A
number of exercises have, however, used systematic
reviews to inform priority-setting processes [26,27]. A
comparison of four sources of potential priorities for the
NHS Health Technology Assessment Programme found
that a widespread consultation of healthcare commission-
ers, providers and consumers was the largest source of sug-
gestions, but the success rate of this source, in terms of
being commissioned, was low. Research recommenda-
tions from systematic reviews provided the second largest
source of priorities and the best success rate of all sources.
Discussion
There are at least 24 different instruments available for
assessing the quality of clinical practice guidelines. We did
not find similar tools developed for assessing the quality
of public health or health policy recommendations,
although the domains that are addressed by clinical prac-Page 5 of 7
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public health and health policy recommendations.
Up to now, self-assessment of guidelines using the Guide-
lines for WHO Guidelines checklist has not been success-
ful. Moreover, most guidelines programmes rely on
external review, as well as internal review. WHO should
put into place processes to ensure that both internal and
external review of guidelines is undertaken routinely
using appropriate criteria.
Processes should also be put into place to ensure that
guidelines are monitored routinely to determine if they
are in need of updating. To ensure that this is done as
expeditiously as possible, people who are familiar with
the topic, such as Cochrane review groups, should con-
duct limited searches routinely. Guideline panels should
identify research that would require revision of the guide-
line and searches should focus particularly on this
research. Periodic review of guidelines by experts not
involved in developing the guidelines should also be con-
sidered, and consideration should be given to establishing
guideline panels that are ongoing with members serving
fixed periods with a rotating membership.
Recommendations may need to be adapted to specific set-
tings, can only be implemented in specific settings, and
their impact can only be assessed in specific settings.
WHO headquarters and regional offices, however, should
support member states and those responsible for deciding
and implementing policies to evaluate the impact of their
policies by providing advice regarding impact assessment,
practical support and coordination of efforts. Before-after
evaluations should be used cautiously, if at all, and when
there are important uncertainties regarding the effects of a
policy or its implementation, randomised evaluations
should be used when possible.
Guideline panels should routinely identify important
uncertainties and research priorities. This source of poten-
tial priorities for research should be used systematically to
inform priority-setting processes for global research.
Further work
Work is needed to ensure that the AGREE instrument or a
similar instrument is suitable for assessing the broad
range of guidelines, recommendations and policies that
WHO produces. In particular, its suitability for assessing
public health and health policy recommendations should
be assessed. Additional items should also be added to
address concerns about equity, which are not currently
addressed in the AGREE instrument, and considerations
that are specific to guidelines that are developed interna-
tionally rather than in a specific country or setting. Work
is also needed on developing practical methods to collect
reliable data that can be used in impact evaluations in
LMIC.
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